SOD1 and amyotrophic lateral sclerosis: Recently, two ALS patients who received intrathecal administration of an adeno-associated virus encoding a microRNA targeting the superoxide dismutase type 1 (SOD1) gene had transient improvement in leg strength and a stable vital capacity during a 12-month follow-up period [191], suggesting the therapeutic benefits of downregulating SOD1.